37 results about "ACUTE INFLAMMATIONS" patented technology

The invention provides a method for constructing an animal chronic gouty arthritis model, which comprises the following steps: a hyperuricemia model establishment stage: feeding a tested animal with a special feed containing oteracil potassium and yeast; establishing a chronic gouty arthritis model: repeatedly injecting urate into the tested animal; meanwhile, oteracil potassium is used for intragastric administration of the tested animal. On the basis of feeding with oteracil potassium combined with a special yeast feed, oteracil potassium solution is injected, blood uric acid level fluctuation is induced on the basis of blood uric acid increase, and urate crystals are injected repeatedly, so that the disease cause and pathological process of chronic gouty arthritis are simulated to the greatest extent; a chronic gouty arthritis animal model is successfully established by injecting urate crystals into joints of experimental animals repeatedly for a long time, inducing repeated attack of local acute inflammation of the joints and simulating pathological characteristics of chronic gouty arthritis.

The invention belongs to the technical field of medicinal chemistry, and discloses a modular preparation method and application of a protein degradation agent targeting soluble epoxide hydrolase (sEH). The derivative has a structural general formula as shown in a formula (I), wherein X and Y substituent groups can be randomly combined. The compound can effectively degrade sEH level in cells and living bodies, and shows a remarkable protective effect on acute liver inflammation of mice in the living bodies. Particularly, the compound shows excellent degradation activity (EC50 = 2.9 nM) in 1d, can quickly relieve acute inflammation induced by LPS, and can be used for research and development of drugs for acute inflammation related diseases.

The invention belongs to the technical field of medicine, and discloses application of SHLP2 in preparation of medicine for relieving and treating acute and chronic inflammatory pain, and the amino acid sequence of SHLP2 polypeptide is MGVKFFTLSTRFFPSVQRAVPLWTNS. After the SHLP2 polypeptide is treated in an intrathecal (5 [mu] g / 10 [mu] g / 20 [mu] g) injection mode, the SHLP2 polypeptide shows a good treatment effect in an acute inflammation pain model induced by formalin and capsaicin and a chronic inflammation pain model induced by carrageenan and a complete Freund's adjuvant. The SHLP2 is utilized to target a mitochondrial genome, the effect of relieving acute and chronic inflammatory pain is achieved in a central sheath injection mode, and a target different from a traditional analgesic drug can be searched for treatment of the acute and chronic inflammatory pain.

This invention discloses a *Lactobacillus plantarum* YBE2 and its applications. The *Lactobacillus plantarum* provided by this invention, which produces a high amount of extracellular polysaccharides primarily composed of rhamnose, can simultaneously degrade different types of bile salts, including specifically hydrolyzing glycocholic acid. It also exhibits cholesterol-lowering and acute inflammation-relieving effects. Furthermore, *Lactobacillus plantarum* YBE2 can reduce fat deposition in the abdomen of caged broilers, increase intramuscular fat, promote fatty acid deposition in muscles, and reduce plasma total bile acids, triglycerides, and low-density lipoprotein cholesterol. This significantly improves lipid metabolism and muscle quality in poultry, and can be widely applied in caged broiler farming to promote healthy poultry farming and improve farming efficiency.

This invention relates to the field of intelligent medical technology, and more particularly to a method for early warning of intestinal fibrosis in Crohn's disease based on a large model. The method includes: acquiring intestinal MRI image sequences of Crohn's disease patients; inputting the intestinal MRI image sequences into a pre-trained large model for intestinal structure analysis to locate the initial intestinal fibrosis region; determining whether the degree of intestinal luminal stenosis in Crohn's disease patients meets the standard based on the intestinal stenosis progression index, and adjusting the feature contrast threshold of the large model based on the difference; determining whether the acute inflammation masking effect of Crohn's disease patients is adequate based on intestinal wall edema characterization parameters, and adjusting the T2-weighted imaging modal weights of the large model based on the relative difference; and determining whether the patency of the fibrotic permeation channel in Crohn's disease patients is adequate based on the fibrotic permeation resistivity, and adjusting the boundary loss weights of the large model based on the ratio. This invention improves the accuracy of early warning of intestinal fibrosis in Crohn's disease.

The invention discloses a dual-regulation pharmaceutical composition for sepsis treatment, a preparation method and application, and belongs to the technical field of biological medicine, and the pharmaceutical composition comprises doxorubicin liposome, all-trans retinoic acid phospholipid complex nanoparticles and antibiotics. Preferably, the doxorubicin liposome is prepared from the sialic acid modified doxorubicin liposome, the sialic acid modified all-trans retinoic acid phospholipid compound nanoparticles and meropenem. Dynamic monitoring of myeloid-derived suppressor cells MDSCs and sialic acid binding immunoglobulin type lectin-E (SiglecE) positively expressed myeloid-derived suppressor cells, namely SiglecE + MDSCs cell subsets, in the middle and later periods of sepsis is used as an evaluation index of the immunosuppression state, and dual regulation and control of sepsis acute inflammation and immunosuppression are achieved. The method has remarkable advantages in the aspects of increasing the survival rate, precisely targeting immunosuppression, improving the drug delivery efficiency and the like, and a brand new solution is provided for clinical treatment of sepsis.

The invention discloses an effective part for chemoradiotherapy-induced oral mucositis in traditional Chinese medicinal material white flower and a preparation process of the effective part. The effective part is identified as a flavonoid component through standard substance spectrogram comparison. Tests prove that the production process of the effective part is practical and feasible, and the total flavonoids in the finally obtained extracting solution are greater than or equal to 50%. Besides, pharmacodynamic studies show that the effective part has a remarkable bacteriostasis effect on staphylococcus aureus, escherichia coli and candida albicans, the bacteriostasis rate is larger than or equal to 80%, the effective part has a remarkable treatment effect on rat oral mucosa acute inflammation caused by chemoradiotherapy, and the application prospect of the effective part in the adaptation disease is shown.

The invention provides an application of children Danqing Shuanglian granules in preparation of drugs for treating acute inflammation. The acute inflammation comprises acute upper respiratory tract infection, bronchitis, amygdalitis and pneumonia caused by virus infection (H1N1, H3N2, FluB and HRSV) or abnormal immunoreaction. Raw materials of the granules comprise nauclea officinalis, artemisia apiacea, scutellaria baicalensis and other traditional Chinese medicinal materials and anti-inflammatory regulatory peptide. The preparation process comprises the following steps: extracting volatile oil by steam distillation, extracting effective components by combining microwave assistance and ultrasonic enhancement, carrying out beta-cyclodextrin inclusion on polypeptide to enhance the stability, and finally granulating to obtain granules with the water content of less than or equal to 6%. Experiments show that the inhibition rate of the drug to HRSV under the maximum non-toxic concentration reaches 81.8% + / -2.0%, and the therapeutic index is SIgt; 2, the latency period of ammonia water induced mouse cough can be remarkably prolonged, the cough frequency is reduced, the antiviral, anti-inflammatory and antitussive effects are achieved, and a safe and effective traditional Chinese medicine choice is provided for clinical treatment of viral acute inflammation.

The present application relates to treatment of nasal cavity inflammation and mucus hypersecretion. One aspect of the present invention is a method of treatment of rhinitis and rhinosinusitis, wherein the treatment reduces nasal stuffiness, nasal congestion, and phlegm secretion. Reduction of phlegm secretion from the nasal cavity into the pharynx can also reduce cough frequency from infectious and allergic rhinitis. In the preferred embodiment, FEMA 4557, is an example of a molecule, topically applied to the nasal mucosa, that can be used to treat rhinitis. FEMA 4557 is a potent non-irritating suppressor of acute inflammation in the nasal cavity and sinuses, a property not previously described for other topical cooling agents. Thus, FEMA 4557 and related analogs may have therapeutic utility for treating nasal inflammation and mucus hypersecretion.

A platform of drug delivery based on self-lysis of ECN, a constructing method, and use of the platform are provided. The platform of drug delivery comprises ECN, a Pvhb-GST-PhiX174E circuit genetically introduced into ECN, and a drug encapsulation material. When the platform is used as an anti-cancer drug carrier, the platform delivers a high concentration of chemotherapeutic drugs to a tumor site. Additionally, through the Pvhb-GST-PhiX174E circuit, ECN is induced to lyse in response to tumor microenvironment signals, leading to cell death in the tumor region and enhancing ECN's biosafety in vivo. Furthermore, ECN within the platform of drug delivery based on self-lysis of ECN serves as an immune adjuvant, stimulates the immune cell activity in the tumor site, triggers acute inflammation, and strengthens the anti-tumor effect, thereby achieving multi-modal anti-tumor therapy through live-cell, chemotherapy, and immunotherapy.

The invention belongs to the technical field of drug development, and particularly relates to stigmasterol hydrogen sulfide derivatives and application thereof in anti-inflammation, anti-oxidation and anti-fibrosis. The molecular formula of the stigmasterol hydrogen sulfide derivative is C42H56O4S3. The stigmasterol hydrogen sulfide derivative disclosed by the invention can be used as an anti-inflammatory, anti-oxidation and anti-fibrosis drug, and shows an ear swelling inhibition effect equivalent to that of a positive drug diclofenac in acute inflammation; the pain threshold is obviously improved when the compound is used as an analgesic drug. The compound has good safety, and CCK-8 experiments show that the compound has no significant influence on the survival rate of macrophages under the treatment concentration (2-16 [mu] M), and has low cytotoxicity.

The invention belongs to the technical field of biology, and discloses application of a composition of neoagaro-oligosaccharide and astaxanthin in preparation of a transdermal drug for treating osteoarthritis and a composite gel preparation. The composition provided by the invention comprises neoagaro-oligosaccharide, astaxanthin, carbomer and alginate in a mass ratio of (1-10): (1-10): (0.01-0.5): (0.1-1), and can realize efficient enrichment of neoagaro-oligosaccharide and astaxanthin in an articular cavity through a substance diffusion path of skin penetration, deep tissue diffusion, joint capsule permeation and articular cavity enrichment, so that the content of neoagaro-oligosaccharide and astaxanthin in the articular cavity is improved, and the content of astaxanthin in the articular cavity is reduced. The new agar oligosaccharide and the astaxanthin have an excellent synergistic effect, so that the acute inflammation symptom of gouty osteoarthritis can be efficiently relieved, the progress of the disease course is blocked, the pathological change of joint tissue is repaired, and the new agar oligosaccharide and the astaxanthin have an excellent application prospect in preparation of the transdermal medicine for treating osteoarthritis.

The invention discloses an establishment method and application of a rat acute inflammation model for simulating clinical inflammation, and relates to the technical field of biology. According to the invention, lipopolysaccharide is taken as a modeling drug, continuous intraperitoneal injection is carried out on a rat at the dosage of 20-40 [mu] g / kg, 30-50 [mu] g / kg and 40-60 [mu] g / kg for three days, and expression and release of interleukin-6 are promoted by activating a Toll-like receptor 4 signal channel, so that the acute inflammation model of the rat is established. The established rat acute inflammation model can cause significant increase of inflammatory biomarkers such as interleukin-6, C-reactive protein and alpha1 acid glycoprotein on the basis of not causing rat liver and kidney injury, and is more similar to clinical acute inflammation states; and a new experimental animal model is provided for exploring the influence of acute inflammation on pharmacokinetics of drugs.

Methods for treating acute conditions (e.g., acute conditions comprising acute inflammation), such as cytokine release syndrome, sepsis and acute kidney injury using lipid binding protein-based complexes.

The application discloses a three-layer time sequence regulation type inflammation targeting composite repair system for repairing endometrial injury and a preparation method and application thereof. The system is a three-layer composite structure, which comprises, from outside to inside, (1) an outer ROS response hydrogel layer loaded with anti-inflammatory drugs, which can respond to early high expression of active oxygen to rapidly degrade the drugs, so that acute inflammation is inhibited; (2) a middle layer of targeted delivery and metabolic repair, which is a M1 macrophage membrane pseudo-loaded drug liposome (NMN@M-Lipo), which is exposed after the degradation of the outer hydrogel, actively targets the inflammation lesion through the M1 membrane, and slowly releases nicotinamide mononucleotide (NMN) to restore cell energy metabolism; and (3) an inner layer of cell recruitment and regeneration, which is a decellularized matrix scaffold loaded with SDF-1 alpha, which continuously releases SDF-1 alpha to recruit endogenous stem cells in the later repair stage, and promotes functional regeneration of the endometrium. The application utilizes the time sequence microenvironment changes of endometrial repair, and realizes the cascade regulation of 'anti-inflammation first, metabolic repair second, and regeneration promotion third'. Animal experiments show that the system can significantly restore the reproductive function of the injured endometrium and improve the number of offspring.

The application discloses a high-temperature-resistant self-delivery circular RNA and a synthesis method and application thereof in preparation of anti-inflammatory drugs, and relates to the technical field of biological medicines.The nucleotide sequence of the high-temperature-resistant self-delivery circular RNA is shown as SEQ ID NO.1.Through nucleic acid extraction and high-throughput sequencing analysis on the decoction of Radix Curcumae, combined with a reverse splicing site identification method, a specific circular RNA is screened and named as circW77.Further research shows that the circW77 can stably exist in a 100 DEG C environment and can significantly inhibit the expression of inflammation-related factors, thereby playing an anti-inflammatory role.Through verification of an in-vitro cell inflammation model, it is found that the circW77 can enter cells without the aid of a carrier and can effectively reduce the transcription and secretion of proinflammatory factors;in-vivo research shows that the circW77 can relieve acute inflammation and non-alcoholic fatty liver inflammation.

A catastrophe-theoretic approach is provided for predicting an occurrence of an acute inflammatory condition or event (e.g., SIRS or sepsis) for a human patient based on a time series of monitored vital signs values measured from a patient, and in some instances, for providing advanced notice to clinicians or caregivers when such an acute inflammatory event is forecasted or modifying treatment for the patient, according to the predicted likelihood. In particular, an acute inflammatory condition management system is provided for determining a likelihood of near-term future significant acute inflammation in human patients. Embodiments of the disclosure described herein may provide a forecasted risk for future significant acute inflammation within a time horizon comprising a future time interval. In one embodiment, the future time interval is from 30 min to approximately 8 hours into the future, and may be dependent on the frequency of vital signs measurements.

The invention provides application of plant lactobacillus in prevention and / or treatment of acute inflammation caused by LPS, and relates to the technical field of microorganisms, for mice with acute inflammation caused by LPS, plant lactobacillus DY6 can inhibit immune system transition activation and lymphocyte abnormal proliferation by adjusting blood routine indexes and visceral organ indexes; the anti-inflammatory effect is achieved by down-regulating inflammatory factors and neutrophil infiltration markers and inhibiting a TLR4 signal channel; redox balance is adjusted, intestinal flora unbalance is improved, and the effect of preventing and / or treating acute inflammation caused by LPS is achieved.

The application provides a fast-acting flunixin meglumine injection and a preparation method thereof, and belongs to the technical field of veterinary medicine, and contains the following components: flunixin meglumine 5-10 (w / v) %, alpha-pyrrolidone 10-30 (w / v) %, hydrophilic solvent 0.5-1 (w / v) %, antioxidant 0.1-0.3 (w / v) % and the balance of water for injection. The application takes flunixin meglumine as the main drug, matches alpha-pyrrolidone as a solvent and a targeting guide distribution component, uses a hydrophilic solvent to assist dissolution and promote absorption, and uses an antioxidant to inhibit the oxidative degradation of the main drug, so that the dissolution and absorption rate of the main drug and the target tissue distribution efficiency can be effectively improved, the storage stability can be ensured, the bacterial endotoxin and the injection site redness rate meet the requirements, the acute inflammation and pain of livestock and poultry can be quickly and efficiently relieved, and the demand for instant intervention in large-scale breeding can be met.

The invention discloses an application of (1S, 2S, 4R)-1-methyl-2, 4-bis (prop-1-ene-2-yl)-1-vinylcyclohexane (alias, beta-elemene) in preparation of a medicine, and the medicine is used for treating or preventing diseases related to acute inflammation, such as acute inflammation, acute inflammation, acute inflammation, acute inflammation and acute inflammation. Comprise acute lung injury related to sepsis caused by lipopolysaccharide (LPS), acute edema pancreatitis induced by ceratidine and severe necrotizing pancreatitis induced by L-arginine, but are not limited to the inducers, and specifically, the inducers can be used for inducing acute lung injury related to sepsis caused by lipopolysaccharide (LPS), acute edema pancreatitis induced by ceratidine and severe necrotizing pancreatitis induced by L-arginine. The medicine can inhibit or improve pathological injury and inflammatory response of lung tissue and pancreatic tissue of acute lung injury and acute pancreatitis.

The invention provides bacteriostatic gel for women and a preparation method thereof, and belongs to the technical field of gynecological gel. The gel comprises 97%-99% of a multi-layer structure base material and 1%-3% of a natural plant effective component. The effective components comprise seven natural components such as a fructus cnidii extract, a helichthys italica extract and a radix sophorae flavescentis extract, and the base material comprises multiple layers of hydrogel. In the use process of the bacteriostatic gel for women, the fructus cnidii extract and the radix sophorae flavescentis extract can directly kill pathogenic bacteria of bacterial vaginitis and have an inhibition effect on HPV viruses, and the tea leaf extract and the psidium guajava leaf extract have antioxidant and bacteriostatic characteristics, so that the capacity of removing harmful microorganisms can be further enhanced. And the base material comprising multiple layers of hydrogel not only can enable bacteriostatic and anti-inflammatory components to continuously act on a focus part and improve the treatment effect on vaginitis and vulvitis, but also can reduce direct stimulation of subsequent effective components on sensitive mucous membranes, and is especially suitable for mucous membrane fragile scenes such as gynecologic operations and acute inflammation stages.

The invention relates to the technical field of intelligent medicine, in particular to a Crohn disease intestinal fibrosis condition early warning method based on large model driving, which comprises the following steps: acquiring an intestinal MRI image sequence of a Crohn disease patient; inputting the intestinal MRI image sequence into a pre-trained intestinal structure analysis large model, and positioning the position of an initial intestinal fibrosis region; determining whether the intestinal lumen stenosis degree of the patient with the Crohn disease reaches the standard or not based on the intestinal lumen stenosis progress index, and determining a feature comparison threshold value for adjusting the large model according to the difference value; determining whether the acute inflammation shielding effect of the patient with the Crohn disease is qualified or not based on the intestinal wall edema characterization parameters, and determining and adjusting the T2 weighted imaging modal weight of the large model according to the relative difference; and determining whether the fibrosis seepage channel smoothness of the patient with the Crohn disease is qualified or not based on the fibrosis seepage resistivity, and determining and adjusting the boundary loss weight of the large model according to the ratio. The early warning accuracy of the intestinal fibrosis condition of the Crohn's disease is improved.

The application discloses a strong external use Chinese herbal medicine composition and a preparation method and application thereof, and belongs to the technical field of external use Chinese herbal medicine preparations. The composition is prepared by compounding active ingredients of genuine Chinese medicinal materials and compliant external use matrix auxiliary materials, is strict in compatibility, is balanced in medicinal properties, and contains core medicinal materials of safflower, twinleaf, dandelion, rhubarb and bloodfly, and has multiple effects of clearing heat and resolving toxins, promoting blood flow and removing blood stasis, removing swelling and relieving pain, removing corruption and promoting tissue regeneration, and inhibiting bacteria and repairing. The application adopts a standardized preparation process of water extraction and concentration, homogeneous mixing and sterile filling, has a simple process, high stability, and is suitable for industrialized batch production, and can be prepared into two types of external use dosage forms of gels and creams. The gel dosage form is refreshing and breathable, is suitable for exudation wound surfaces, acute inflammation stages and summer use; the cream dosage form is nourishing and slow-releasing, is suitable for deep layer stasis and swelling, dry and indurated wound surfaces and winter maintenance use, the product is suitable for a wide range of scenes, is gentle and safe in medicinal properties, and is outstanding in clinical practicability and market value.

The invention belongs to the technical field of biomedicine, and particularly relates to an acute plateau low-pressure low-oxygen lung injury mouse model building method which comprises the following steps: selecting SPF-level male SD (Sprague Dawley) rats for adaptive feeding; performing low-oxygen sensitivity pretreatment on the rats after the adaptive feeding is finished; debugging the closed low-pressure oxygen cabin to an initial standard state, putting the pretreated rat into the closed low-pressure oxygen cabin, and closing the cabin door; performing staged low-pressure and low-oxygen synergistic exposure on the rats in the cabin, and obtaining an acute plateau low-pressure and low-oxygen lung injury rat model after the exposure is finished; according to the method, a staged low-pressure low-oxygen collaborative exposure design of pressure dominated low oxygen and oxygen concentration collaborative low oxygen is adopted, so that the core characteristic that the natural plateau oxygen partial pressure is gradually reduced along with the altitude is completely reproduced; the periodic fluctuation mode of the oxygen concentration cooperation stage further fits the oxygen concentration change of the real plateau environment, and it is ensured that the model can truly reproduce the progressive pathological process from the initial hypoxia stress to the acute inflammation injury.

The invention relates to an application of Kp1 (at) HCeO2 (at) SAM in preparation of drugs for treating or improving inflammatory bowel diseases, and the Kp1 (at) HCeO2 (at) SAM is prepared by embedding KP1-loaded HCeO2 composite nanoparticles into SAM. The invention further provides the Kp1 (at) HCeO2 (at) SAM for treating or improving the inflammatory bowel disease and a preparation method of the Kp1 (at) HCeO2 (at) SAM. According to the invention, the oral KP1 (at) HCeO2 (at) SAM composite microspheres are constructed, so that the acute inflammatory response of IBD is coordinated and intervened, and the chronic fibrosis process is reversed. In a DSS-induced mouse colitis model, the platform shows a staged curative effect: in an acute inflammation stage, HCeO2 efficiently clears active oxygen, promotes macrophage to be converted into M2 anti-inflammatory phenotype and reduces inflammatory factor expression, so that intestinal barrier function recovery is promoted; in the chronic fibrosis period, the sustained-release KP1 oligopeptide can inhibit a TGF-beta / Smad pathway in a targeted mode, myofibroblast activation and collagen deposition are remarkably inhibited, and therefore intestinal fibrosis lesion is reversed. Therefore, the composite microsphere disclosed by the invention, as a novel oral preparation for treating IBD, shows a wide clinical application prospect.

The present application relates to the technical field of pharmaceutical chemistry, in particular to a preparation method and application of a berberine and isovitexin nanomedicine. The application is used in the preparation of a drug for treating diseases related to inflammation mediated by neutrophils. The berberine and isovitexin or the structural analogues of berberine and isovitexin form nanoparticles in a carrier-free form through self-assembly. The berberine and isovitexin nanomedicine has a synergistic anti-inflammatory and antioxidant effect, can efficiently inhibit key inflammatory mediators, realize high-efficiency anti-inflammatory and antioxidant synergy, and significantly improve the effect of preventing and treating acute inflammation.

The invention discloses a quinazolinone BRD4 inhibitor and a preparation method thereof, and belongs to the technical field of medicines. The inhibitor is a compound represented by a general formula (I), a pharmaceutically acceptable salt thereof or a stereoisomer thereof, wherein R1-R8, X or Y are defined in the specification. The invention also relates to a preparation method of the compounds, and a pharmaceutical preparation or a pharmaceutical composition containing the compounds. The BRD4 inhibitor can remarkably inhibit the activity of BRD4 protein, the NO generation inhibition activity is higher than that of a clinical test drug RVX-208, and the BRD4 inhibitor is expected to be applied to preparation of drugs for preventing or / and treating inflammation, especially to preparation of drugs for preventing or / and treating acute inflammation (such as septicemia), and has a remarkable medicinal prospect.

The invention provides a traditional Chinese medicine ointment for reducing swelling, removing stasis and relieving pain and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine ointment provided by the invention has the remarkable effects of promoting blood circulation to remove blood stasis and relieving swelling and pain, can quickly relieve pain and alleviate swelling, and is suitable for various common inflammation and pain symptoms, such as parotitis, furuncle, scapulohumeral periarthritis and lumbar muscle strain; based on traditional Chinese medicine experience, the traditional Chinese medicine composition is simple in preparation process, convenient to use, capable of improving symptoms of patients and reducing pain within a short time without complex operation, high in safety and free of definite adverse reaction, has wide clinical application prospects and popularization value, and is beneficial for making up for the defects of modern medicine in part of chronic diseases and acute inflammation.

The invention discloses a preparation method and application of a quinazolinone-diketopiperazine heterozygote BRD4 inhibitor, belongs to the technical field of medicines, and particularly relates to the quinazolinone-diketopiperazine heterozygote BRD4 inhibitor shown in a general formula (I), pharmaceutically acceptable salt or stereoisomer thereof, and R1-R8, X, Y, Z or W are defined in the specification. The invention also relates to a preparation method of the compounds, and a pharmaceutical preparation or a pharmaceutical composition containing the compounds. The quinazolinone-diketopiperazine heterozygote BRD4 inhibitor provided by the invention has strong inhibitory activity (IC50 = 0.92 nM) and high selectivity (170323 times) on a second bromo-domain, which is stronger than that of a clinical test drug RVX-208 (17 times), and NO generation inhibitory activity is stronger than that of RVX-208, so that the quinazolinone-diketopiperazine heterozygote BRD4 inhibitor is expected to be applied to preparation of drugs for preventing or / and treating inflammation, and has broad application prospects. The compound can be particularly applied to preparation of drugs for preventing or / and treating acute inflammation (such as septicemia), and has a remarkable medicinal prospect.

The invention provides a method for regulating and controlling hematopoietic balance based on a Jak2 / Stat3-Hif1a signal channel and application of the method, and belongs to the field of biotechnology and medicine. According to the method, by regulating and controlling a Jak2 / Stat3-Hif1a signal channel, hematopoietic system unbalance caused by factors such as acute inflammation or acute hypoxia is intervened or reversed. Aiming at the problems that in the prior art, mechanism cognition is not clear, intervention targets are not clear, pathway relevance research is insufficient and the like, the molecular mechanism of acute inflammation affecting hematopoietic balance is deeply explored, and the internal relation of a Jak2 / Stat3 pathway and Hif1alpha for regulating and controlling hematopoietic balance under the acute stress condition is disclosed. The invention can be applied to preparation of medicines for treating blood system diseases caused by factors such as acute inflammation and hypoxia, particularly provides a targeted intervention strategy for accurately correcting hematopoietic lineage migration aiming at diseases such as sepsis-related anemia, and has important clinical application value.